| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
3 companies
Espinoza Octavio serves as a Chief Financial Officer at LGNZZ and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 2 buys and 25 sells. Those positions are worth an estimated $10.4M at current prices.
Historically, Espinoza Octavio's trades have earned a below-average insider score of 48/100 across 10 rated trades. Over a 12-month horizon, 22.2% of those trades were profitable, with an average 12-month return of -21.3%.
The biggest single holding is LGND (~$4.5M) as Chief Financial Officer. The recent filings there lean toward selling, a net 37,235 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | LGNZZ Ligand Pharmaceuticals Incorporated | Chief Financial Officer | Sale+OE10b5-1 | 31,641 | $292.07 | $9,241,228.67 | -53.3% | - | - | |
| Mar 11, 2026 | LGNZZ Ligand Pharmaceuticals Incorporated | Chief Financial Officer | Sale+OE10b5-1 | 3,057 | $225.00 | $687,825.00 | -12.7% | - | - | |
| Mar 4, 2026 | LGND Ligand Pharmaceuticals Incorporated | Chief Financial Officer | Sale+OE10b5-1 | 13,423 | $205.83 | $2,762,822.25 | -38.3% | +11.4% | - | |
| Dec 12, 2025 | LGND Ligand Pharmaceuticals Inc | Chief Financial Officer | Sell | 1,804 | $188.31 | $339,711.24 | -6.4% | +11.6% | - | |
| May 9, 2025 | LGND Ligand Pharmaceuticals Inc | Chief Financial Officer | Buy | 1,500 | $104.06 | $156,090.00 | +5.7% | +40.0% | +111.9% | |
| Mar 4, 2025 | LGND Ligand Pharmaceuticals Inc | Chief Financial Officer | Sell | 5,000 | $115.03 | $575,148.50 | -20.9% | -11.8% | +81.3% | |
| Dec 23, 2024 | LGND Ligand Pharmaceuticals Inc | Chief Financial Officer | Sell | 2,104 | $116.37 | $244,850.48 | -9.2% | -1.9% | +73.5% | |
| Sep 20, 2024 | LGND Ligand Pharmaceuticals Inc | Chief Financial Officer | Sell | 1,275 | $103.94 | $132,518.19 | -4.9% | +10.8% | +62.0% | |
| May 17, 2024 | LGND Ligand Pharmaceuticals Inc | Chief Financial Officer | Sale+OE | 13,293 | $86.26 | $1,146,703.87 | -36.2% | +19.8% | +21.5% | |
| Feb 28, 2024 | LGND Ligand Pharmaceuticals Inc | Chief Financial Officer | Sale+OE | 140 | $88.46 | $12,384.40 | -0.5% | +1.9% | +37.1% |